Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 6/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29831 | 1.00 | LMNA (0.40) | LMNAMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL30879 | 1.00 | LMNA (0.40) | LMNAMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL30793 | 1.00 | LMNA (0.40) | LMNAMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL8928218 | 1.00 | LMNA (0.40) | LMNAMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL2801674 | 1.00 | LMNA (0.40) | LMNAMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL31034 | 1.00 | — | — | |
| SCHEMBL30759 | 1.00 | — | — | |
| SCHEMBL2795953 | 1.00 | LMNA (0.40) | LMNAMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL30599 | 0.97 | — | — | |
| SCHEMBL16595111 | 0.91 | GAA (0.47) | LMNAMEN1KMT2ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1969814-B | Nasal administered preparation of melatonin | INST PHARM & TOXICOLOGY AMMS | 2010-05-26 | — | — | CN | claimed |
| CN-1969814-A | Nasal administered preparation of melatonin | POISON MED INST PLA MED ACAD (CN) | 2007-05-30 | — | — | CN | claimed |
| US-5077199-A | Comprising glucose oxidase free from catalase and nonionic surfactant stabilizer | A. MENARINI S.A.S. (IT) | 1991-12-31 | — | — | US | claimed |
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | SEAPORT THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | PURETECH LYT, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-11938137-B2 | Lipid prodrugs of mycophenolic acid and uses thereof | PURETECH LYT, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240066436-A1 | BIOBASED DEFOAMER COMPOSITIONS AND METHODS OF PREPARATION THEREOF | KRATON CHEMICAL, LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240050573-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2024-02-15 | — | — | US | disclosed |
| US-11883497-B2 | Lymphatic system-directing lipid prodrugs | PURETECH LYT, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4306524-A2 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | PureTech LYT, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230416557-A1 | ANTIFOG COMPOSITIONS AND ARTICLES MADE THEREOF | Kraton Corporation (US) | 2023-12-28 | — | — | US | disclosed |
| US-20120207818-A1 | COMPOSITION FOR SUPPRESSING EXPRESSION OF TARGET GENE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8100135-B2 | Hair coloring system and test device capable of being used in such a system | L'OREAL S.A. (FR) | 2012-01-24 | — | — | US | disclosed |
| EP-1648262-B1 | HAIR COLORING SYSTEM AND TEST DEVICE CAPABLE OF BEING USED IN SUCH A SYSTEM | OREAL (FR) | 2009-07-29 | — | — | EP | disclosed |
| US-20070180895-A1 | Hair coloring system and test device capable of being used in such a system | L'OREAL S.A. (FR) | 2007-08-09 | — | — | US | disclosed |
| US-20070179227-A1 | VOC-free water reducible coating vehicles | VOCFREE, INC. | 2007-08-02 | — | — | US | disclosed |
| EP-1648262-A1 | HAIR COLORING SYSTEM AND TEST DEVICE CAPABLE OF BEING USED IN SUCH A SYSTEM | L'OREAL (FR) | 2006-04-26 | — | — | EP | disclosed |
| US-20050148711-A1 | VOC free water reducible coating vehicles | VOCFREE, INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005013759-A1 | HAIR COLORING SYSTEM AND TEST DEVICE CAPABLE OF BEING USED IN SUCH A SYSTEM | L'OREAL (FR) | 2005-02-17 | — | — | WO | disclosed |
| EP-0422599-A1 | Antigen-sensitized bead and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938137-B2 | Lipid prodrugs of mycophenolic acid and uses thereof | MALT1, CYP2B6, LIPA | LMNA 4002/4885MEN1 1358/4885KMT2A 1823/4885 |
| US-20240050573-A1 | LYMPH DIRECTING PRODRUGS | LTA, ABCB11, LYN | LMNA 3766/4885MEN1 2306/4885KMT2A 4086/4885 |
| US-11883497-B2 | Lymphatic system-directing lipid prodrugs | LIPA, MALT1, SGMS1 | LMNA 2779/4885MEN1 1498/4885KMT2A 2872/4885 |
| US-20240207411-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | LIPA, MALT1, SGMS1 | LMNA 2779/4885MEN1 1498/4885KMT2A 2872/4885 |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | CYP21A2, CYP46A1, CYP17A1 | LMNA 2962/4885MEN1 518/4885KMT2A 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.